# Measles and rubella elimination country profile Spain 

Measles elimination status


Source:European Regional Verification Commission for Measles and Rubella Elimination (RVC) meeting report: www.euro.who.int/6thRVC

National plan of action


Source: Measles and rubella elimination Annual Status Update report, 2016 ND= Data not available

Measles and rubella immunization schedule, 2016

|  | Vaccine | Schedule | Year of introduction |  |
| :---: | :---: | :---: | :---: | :---: |
| MCV1 | MMR | 12 <br> months | MCV2 | 1996 |
| MCV2 | MMR | $3-4$ years | RCV | 1978 |
| Measles vaccination in school |  |  |  | No |

Source: Immunization schedule, WHO, Data and Statistics, Immunization Monitoring and Surveillance (http://umw.who.int/immunization/monitoring_surveillance/data/en/)
MMR = measles-mumps-rubella-containing vaccine; $M C V 1$ = first dose measles-containing vacccine; MCV2 = second dose measles-containing vaccine; RCV = rubella-containing vaccine

Definition used for an outbreak

2 or more confirmed cases which are temporally related (with dates of rash onset occurring between 7 and 18 days apart for measles and with dates of rash onset occurring between 12 and 46 days apart for rubella) and epidemiologically or virologically linked or both

Source: Measles and rubella elimination Annual Status Update report, 2016

Rubella elimination status

2015 eliminated
2016 eliminated

Source:European Regional Verification Commission for Measles and Rubella Elimination (RVC) meeting report: www.euro.who.int/bthRVC

Demographic information, 2016

| Total population | 46064604 |
| :---: | :---: |
| < 1 year old | 411803 |
| < 5 years old | 2042034 |

Source: World Population Prospects: The 2015 Revision, New York, United Nations

Measles and rubella cases and immunization coverage, 2007-2016


Source: Disease incidence and immunization coverage, WHO, Data and Statistics, Immunization Monitoring and Surveilance
(http://www.who.int/immunization/monitoring_surveillance/data/en/)
MCV1 = first dose of measles-containing vaccine
MCV2 = second dose of measles-containing vaccine

Confirmed measles cases by month of onset, 2012-2016


Source: CISID2 2016

Measles cases by first subnational level, 2016


Measles genotypes by first subnational level, 2016


Source: MeaNS 2016
Sarce Mens

Ten
Note: The dots in the maps are placed randomly within the administrative regions
Map disclaimer: The boundaries and names shown and the designations used on the maps do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

Measles cases by age group and vaccination status, 2016


Source: Measles and rubella elimination Annual Status Update report, 2016

Sources of infection, 2016

|  | Measles | Rubella |
| :---: | :---: | :---: |
| Imported | 11 | 1 |
| Import-related | 23 | 1 |
| Unknown/ Not <br> reported | 1 | 0 |
| Endemic | 0 | 0 |

Source: Measles and rubella elimination Annual Status Update report, 2016

Information on CRS, 2016


[^0]
# Measles and rubella elimination country profile Spain 

Measles incidence, epidemiologic and virologic characteristics, 2012-2016

|  | Suspected measles cases | Confirmed measles cases |  |  |  | $\begin{gathered} \text { Discarded } \\ \text { as } \\ \text { non- } \\ \text { measles } \end{gathered}$ | Measles incidence | Genotypes detected |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Laboratory | Epilinked | Clincally | Total |  |  |  |
| 2012 | ND | 713 | 243 | 148 | 1204 | ND | 25 | B3,D4, D8 |
| 2013 | 217 | 109 | 14 | 8 | 131 | 86 | 2.5 | B3,D8 |
| 2014 | 339 | 150 | 3 | 6 | 159 | 181 | 3.3 | B3,D8 |
| 2015 | 115 | 32 | 3 | 2 | 37 | 78 | 0.8 | B3, D8, H 1 |
| 2016 | 98 | 27 | 8 | 0 | 35 | 63 | 0.8 | B3, D8 |

Source: Measles and rubella elimination Annual Status Update report, 2012-2016
ND = Data not available: $N A=$ Not applicable

Rubella incidence, epidemiologic and virologic characteristics, 2012-2016

|  | $\begin{array}{c}\text { Suspected } \\ \text { rubella } \\ \text { cases }\end{array}$ | Confirmed measles cases |  |  |  |  | $\begin{array}{c}\text { Discarded } \\ \text { as } \\ \text { non- } \\ \text { rubella }\end{array}$ | $\begin{array}{c}\text { Rubella } \\ \text { incidence }\end{array}$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | \(\left.\begin{array}{c}Genotypes <br>

detected\end{array}\right)\)

Source: Measles and rubella elimination Annual Status Update report, 2012-2016, and internal communication from country ND = Data not available: $\mathrm{NA}=$ Not applicable

Measles surveillance and laboratory performance indicators, 2012-2016

|  | Discarded <br> non- <br> measles <br> rate | \% 1st sub- <br> national <br> unit with <br> $\geqslant 2$ <br> discarded <br> cases | \% cases <br> with <br> adequate <br> laboratory <br> investiga- <br> tion | \% origin of <br> infection <br> known | $\#$ <br> specimen <br> tested for <br> measles | \% positive <br> for <br> measles | Rate of <br> viral <br> detection | \% WHO <br> and <br> proficient <br> labs |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 2012 | ND | ND | $92.6 \%$ | $54.6 \%$ | 1517 | $73 \%$ | ND | ND |
| 2013 | $18 \%$ | $0 \%$ | $92.2 \%$ | $96.2 \%$ | 324 | $49 \%$ | $68.8 \%$ | ND |
| 2014 | $38 \%$ | ND | $98.8 \%$ | $96.2 \%$ | 383 | $50 \%$ | $100 \%$ | ND |
| 2015 | $17 \%$ | ND | $90.4 \%$ | $86.5 \%$ | 158 | $32 \%$ | $100 \%$ | $100 \%$ |
| 2016 | $14 \%$ | $0 \%$ | $91.8 \%$ | $97 \%$ | 135 | $33 \%$ | $100 \%$ | $100 \%$ |

Source: ASU 2012-2016, MeaNS 2012-2016 and laboratory accreditation results 2012-2016, and internal communication from country $\mathrm{ND}=$ Data not avalable; $\mathrm{NA}=$ Not applicable
accredited and/or has an established quality assurance programme with oversight by a WHO accredited laboratory

Rubella surveillance and laboratory performance indicators, 2012-2016

|  | Discarded <br> non- <br> rubella <br> rate | \% 1st sub- <br> national <br> unit with <br> $\geqslant 2$ <br> discarded <br> cases | \% cases <br> with <br> adequate <br> laboratory <br> investiga- <br> tion | $\%$ origin of <br> iffection <br> known | $\#$ <br> specimen <br> tested for <br> rubella | \% positive <br> for rubella | Rate of <br> viral <br> detection | \% WHO <br> and <br> porficient <br> labs |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 2012 | ND | ND | $91.2 \%$ | $84 \%$ | 86 | $80 \%$ | ND | ND |
| 2013 | 0 | $0 \%$ | $94.1 \%$ | $100 \%$ | 26 | $12 \%$ | ND | ND |
| 2014 | 0 | ND | $86.4 \%$ | $60 \%$ | 30 | $37 \%$ | $100 \%$ | ND |
| 2015 | 0.1 | ND | $93.1 \%$ | $50 \%$ | 30 | $30 \%$ | ND | $100 \%$ |
| 2016 | 0 | ND | $100 \%$ | $100 \%$ | 13 | $23 \%$ | ND | $100 \%$ |

from country ND = Data not available; NA = Not applicable
A proficient laboratory is WHO accredited and/or has an established quality assurance programme with oversight by a WHO accredited laboratory

## RVC comments, based on 2016 reporting

The Regional Verification Commission for Measles and Rubella Elimination (RVC) concluded that endemic transmission of both measles and rubella remained interrupted in Spain in 2016. The RVC confirmed that rubella elimination has been sustained and, considering the conclusions of the interrupted status of measles transmission in 2014 and 2015, the RVC is pleased to declare that Spain has achieved elimination of measles. The RVC commends Spain on the improvements made in case investigation, laboratory confirmation and genotyping, and providing additional information on rubella through review of CRS cases in hospital registries. The RVC urges the national health authorities to maintain high-quality surveillance and take appropriate measures to ensure high MRCV coverage.

Source: Regional Verification Commission for Measles and Rubella Elimination (RVC) meeting report (www.euro.who.int/bthRVC)

## Surveillance performance indicators and targets

a. Rate of discarded cases: at least 2 discarded measles or rubella cases per 100000 population
b. $\%$ cases with adequate laboratory investigation: $\geqslant 80 \%$
c. \% origin of infection known: $\geqslant 80 \%$
d. Rate of viral detection: $\geqslant 80 \%$


[^0]:    Source: Measles and rubella elimination Annual Status Update report, 2016
    CRS = congenital rubella syndrome

